Trials / Completed
CompletedNCT06184360
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,079 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).
Conditions
Timeline
- Start date
- 2022-05-31
- Primary completion
- 2022-06-30
- Completion
- 2022-12-16
- First posted
- 2023-12-28
- Last updated
- 2023-12-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06184360. Inclusion in this directory is not an endorsement.